Viridian Therapeutics, Inc.\DE (VRDN) Company Report

The Biologics License Application (BLA) for veligrotug in thyroid eye disease (TED) has been accepted for Priority Review by the FDA, with a PDUFA target action date of June 30, 2026. A Marketing Authorization Application (MAA) for veligrotug is also expected to be submitted to the European Medicines Agency in Q1 2026.
Topline Phase 3 results for subcutaneous elegrobart (VRDN-003) are anticipated in Q1 2026 for active TED (REVEAL-1) and Q2 2026 for chronic TED (REVEAL-2).
Viridian submitted an Investigational New Drug (IND) application for VRDN-008 in December 2025, with healthy volunteer data expected in 2H 2026. The company also plans to submit an IND for a new thyroid-stimulating hormone receptor (TSHR) inhibitor program in Q4 2026.
As of October 31, 2025, Viridian Therapeutics held approximately $888 million in cash and investments, and anticipates funding its current business plans through profitability.

Jan 6, 2026, 12:01 PM

Viridian Therapeutics' Veligrotug BLA Accepted with Priority Review

VRDN

Product Launch

New Projects/Investments

Viridian Therapeutics announced the FDA's acceptance of its Biologics License Application (BLA) for veligrotug for Thyroid Eye Disease (TED), granting it Priority Review.
The PDUFA target action date for veligrotug is June 30, 2026, indicating a shortened six-month review period.
Veligrotug previously received Breakthrough Therapy Designation in May 2025, with both designations supported by strong Phase 3 clinical trial data showing significant improvement in chronic TED symptoms.
The BLA is supported by positive data from two Phase 3 trials (THRIVE and THRIVE-2) that met all primary and secondary endpoints, demonstrating rapid clinical benefit and good tolerability.
Viridian is preparing for an anticipated commercial launch and plans to submit a Marketing Authorization Application to the European Medicines Agency in the first quarter of 2026.

Dec 22, 2025, 12:00 PM

Viridian Metals Reports Initial 2025 Drill Results

VRDN

New Projects/Investments

Viridian Metals Inc. announced initial assay results from the first five holes of its 2025 drilling program at the Kraken Main Zone, confirming continuous, near-surface sulphide mineralization across 80 metres of strike.
The results included local high-grade copper zones such as 1.38% Cu (2.14% CuEq) over 0.7 metres from 4.45 metres depth, with several holes returning >20-metre mineralized intervals.
The company has now drill-tested the mineralized unit across 674 metres of strike, confirming continuity over more than 600 metres of trend.
Assays for an additional 360 metres of drilled strike at the Kraken Main Zone are currently pending, with results expected over the coming months.
Planning has begun for an expanded 2026 drilling program that will continue step-outs along the 5-kilometre anomaly and test newly identified structural splays.

Dec 10, 2025, 1:00 PM

Viridian Therapeutics Announces Q3 2025 Financial Results and Key Pipeline Progress

VRDN

Earnings

Debt Issuance

Product Launch

Viridian Therapeutics completed comprehensive financing transactions in October 2025, securing access to up to $889 million of potential capital, including $289.1 million gross proceeds from a public equity offering. This resulted in a cash position of approximately $887.9 million as of October 31, 2025, and the company believes it is funded through profitability.
The company successfully submitted a Biologics License Application (BLA) for veligrotug to the U.S. FDA in October 2025, with an anticipated U.S. commercial launch in mid-2026 if approved under Priority Review.
Topline data readouts for subcutaneous VRDN-003 in active and chronic Thyroid Eye Disease (TED) (REVEAL-1 and REVEAL-2) have been accelerated to Q1 2026 and Q2 2026, respectively, with a BLA submission planned for year-end 2026.
For the third quarter ended September 30, 2025, Viridian reported $70.6 million in total revenue, primarily from license revenue, and a net loss of $(34.6 million).

Nov 5, 2025, 12:09 PM

Viridian Therapeutics Submits BLA for Veligrotug in Thyroid Eye Disease

VRDN

Product Launch

New Projects/Investments

Viridian Therapeutics successfully submitted a Biologics License Application (BLA) to the U.S. FDA in late October for veligrotug, an investigational therapy for Thyroid Eye Disease (TED).
The BLA is supported by positive data from two pivotal phase 3 clinical trials, THRIVE and THRIVE-2, and veligrotug has been granted Breakthrough Therapy Designation, which supports eligibility for potential Priority Review.
An FDA decision on whether to accept the BLA for filing is expected within 60 days of submission, with a potential mid-2026 commercial launch if approved and granted Priority Review.

Nov 3, 2025, 12:01 PM

Viridian Therapeutics Prices Public Offering

VRDN

New Projects/Investments

Convertible Preferred Issuance

Viridian Therapeutics has priced an underwritten public offering of 11,425,000 shares of common stock at $22 per share, expected to raise approximately $251 million before expenses.
The proceeds from this offering will fund commercial launch activities for its thyroid eye disease (TED) treatments veligrotug and VRDN-003, research and development, working capital, and general corporate purposes.
The company also commenced an offering of Series B non-voting convertible preferred stock, which can be converted into common stock at a rate of 1 preferred share to 66.67 common shares.
Despite strong recent stock momentum and positive analyst sentiment, Viridian faces significant financial challenges, including operating losses with an operating margin of approximately -121,831% and a negative three-year revenue growth rate of -74.8%.